ESSA Pharma Inc (EPIX)

26.79
-0.43(-1.58%)
  • Volume:
    127,126
  • Bid/Ask:
    26.80/34.00
  • Day's Range:
    26.53 - 27.58

EPIX Overview

Prev. Close
27.22
Day's Range
26.53-27.58
Revenue
-
Open
27.12
52 wk Range
4.92-36
EPS
-0.92
Volume
127,126
Market Cap
1.08B
Dividend (Yield)
N/A
(N/A)
Average Vol. (3m)
244,422
P/E Ratio
-
Beta
1.66
1-Year Change
430.5%
Shares Outstanding
40,455,622
Next Earnings Date
Aug 17, 2021
What is your sentiment on ESSA Pharma Inc?
or
Market is currently closed. Voting is open during market hours.

ESSA Pharma Inc News

  • ESSA Pharma reports Q1 results
    • BySeeking Alpha-

    ESSA Pharma (EPIX): Q1 GAAP EPS of -$0.36.At March 31, 2021, the Company had available cash reserves and short-term investments of $208,597,224 reflecting the gross proceeds of...

  • ESSA Pharma prices equity offering at $27
    • BySeeking Alpha-

    ESSA Pharma (EPIX) has priced its public offering of ~4.8M common shares at $27.00/share, for gross proceeds of ~$130.4M.Underwriters' over-allotment is an additional ~724.6K...

ESSA Pharma Inc Analysis

Technical Summary

Type
5 Min
15 Min
Hourly
Daily
Monthly
Moving AveragesStrong SellStrong SellStrong SellSellBuy
Technical IndicatorsStrong SellStrong SellStrong SellStrong SellStrong Buy
SummaryStrong SellStrong SellStrong SellStrong SellStrong Buy

ESSA Pharma Inc Company Profile

ESSA Pharma Inc Company Profile

Employees
11

ESSA Pharma, Inc. is a Canada-based pharmaceutical company. The Company is focused on developing therapies for the treatment of castration-resistant prostate cancer (CRPC). It is developing EPI-7386 for the treatment of metastatic CRPC (mCRPC). It is also developing EPI-7386 combination therapy for mCRPC. In addition to this, the Company's pipeline also includes antien for triple negative androgen receptor (AR+) breast cancer. Its aniten compounds bind to the N-terminal domain of the androgen receptor (AR), inhibiting AR driven transcription and the AR signaling pathway in a manner which bypasses the drug resistance mechanisms associated with current anti-androgens.

Read More
  • EPIX @$50 in summer 2020 ?
    1
    Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All derived (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data.
    Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.